UT - Houston to Test Alternative Cancer Agents

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

HOUSTON--The University of Texas-Houston Health Science Center has been selected by the National Institutes of Health to be home to one of eight specialty centers that will conduct research into the effectiveness of alternative medicines used in cancer treatment.

HOUSTON--The University of Texas-Houston Health Science Centerhas been selected by the National Institutes of Health to be hometo one of eight specialty centers that will conduct research intothe effectiveness of alternative medicines used in cancer treatment.

UT-Houston is expected to receive $733,350 over a 3-year periodfrom the NIH Office of Alternative Medicine. The research willbe conducted in the Center for Health Promotion Research and Developmentat the School of Public Health.

Guy S. Parcel, PhD, principal investigator and director of theCenter, said that the primary aim of the research will be to evaluatethe effectiveness of biopharmacologic and herbal therapies forcancer prevention and treatment. Biopharmacologic therapies mayinclude biochemical agents, vaccines, blood products, or syntheticchemicals, while herbal therapies are those derived from plantssuch as the mayapple, periwinkle, and Pacific yew tree.

"Despite the widespread use of alternative therapies, manyhave not undergone rigorous scientific testing for their effectivenessand safety," Dr. Parcel said. The first task will be an evaluationof the scientific studies that do exist so that a research agendacan be set, he said. The Center hopes to begin funding projectsin the second year of the grant.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content